Abstract: The present invention relates to a microfluidic chip, a reagent output structure thereof comprising a reagent storage chamber, a first centrifugal-force flow channel and a time delay unit. The time delay unit comprises a first diverting flow channel, a capillary-force flow channel, a second diverting flow channel and a second centrifugal-force flow channel. The first centrifugal-force flow channel extends away from the centre of rotation. The other end of the first diverting flow channel is in communication with one end of the capillary-force flow channel, the capillary-force flow channel extends towards the centre of rotation, the other end of the capillary-force flow channel is in communication with one end of the second diverting flow channel, the other end of the second diverting flow channel is in communication with the second centrifugal-force flow channel, and the second centrifugal-force flow channel extends away from the centre of rotation.

Abstract: The present disclosure discloses a microfluidic chip, a system and a method for automatic separation and detection of circulating tumor cells. The microfluidic chip includes a density gradient centrifugation assembly, a cell capture assembly, and a reagent storage assembly. The density gradient centrifugation assembly is configured to carry out density gradient centrifugation on a whole blood sample to achieve separation and obtain a plasma layer, a monocyte layer, a Ficoll solution layer, and an erythrocyte and granulocyte layer. The cell capture assembly includes a capture channel, a capture inlet, and a capture outlet. The capture inlet and the capture outlet are in communication with the capture channel. An inner wall of the capture channel is provided with capture holes and negative-pressure capture chambers. Each capture hole is in communication with one negative-pressure capture chamber correspondingly.

Abstract: A droplet microfluidic chip and a method for producing microdroplets are disclosed. The droplet microfluidic chip includes at least one droplet-producing unit. The droplet-producing unit includes a dispersion phase chamber, a quantitation chamber, a capillary nozzle, and a continuous phase chamber. The droplet microfluidic chip has a rotation center. The dispersion phase chamber is provided with a loading hole configured to introduce a dispersion phase liquid. The quantitation chamber is in communication with the dispersion phase chamber and further away from the rotation center than the dispersion phase chamber. The capillary nozzle is further away from the rotation center than the quantitation chamber. One end of the capillary nozzle is in communication with the quantitation chamber, and the capillary nozzle is extended from the joining end in a direction away from the rotation center.

Abstract: The present invention relates to the field of pharmaceutical chemistry, and specifically relates to a fused heterocyclic compound derivative and an application thereof. The fused heterocyclic compound derivative has the structure of general formula (I), and can be used to treat neuropsychiatric diseases.

Abstract: The present invention relates to the field of pharmaceutical chemistry, and specifically relates to a fused heterocyclic compound derivative and an application thereof. The fused heterocyclic compound derivative has the structure of general formula (I), and can be used to treat neuropsychiatric diseases.

Abstract: The present invention relates to the field of pharmaceutical chemistry, and in particular, to a benzopyrone derivative and a use thereof. The benzopyrone derivative is compound having a structure of formula (I) or a pharmaceutically acceptable salt thereof. It has been found by experiments that, this type of compounds is useful in prevention or treatment of neuropsychical diseases.

Abstract: Disclosed are alicyclic[c]benzopyrone derivatives and use thereof. The alicyclic[c]benzopyrone derivatives are compounds represented by formula I or their salts. The present compounds not only significantly improve high activity induced by MK-801, but also effectively improve clambering symptom induced by Apomorphine and do not cause EPS within effective dose. These in vitro targets and in vivo pharmacological models are closely related to diseases of the nervous system caused by dopamine dysfunction, especially schizophrenia. Therefore the present compounds can be used for the treatment of central nervous system diseases, especially schizophrenia. ED50 is lower and effect is stronger in two animal models i.e. high activity induced by MK-801 and clambering symptom induced by Apomorphine, while ED50 is higher and therapeutic index is greater in animal models of catalepsy.

Abstract: The present invention belongs to the medicinal chemistry field, and specifically discloses a [1,3,4]oxadiazole derivative with the structure of general formula (I) and pharmaceutically acceptable salt thereof. The compound can be used to prepare a medicine for preventing or treating a disease of the central nervous system.

Abstract: Disclosed are alicyclic[c]benzopyrone derivatives and use thereof. The alicyclic[c]benzopyrone derivatives are compounds represented by formula I or their salts. The present compounds not only significantly improve high activity induced by MK-801, but also effectively improve clambering symptom induced by Apomorphine and do not cause EPS within effective dose. These in vitro targets and in vivo pharmacological models are closely related to diseases of the nervous system caused by dopamine dysfunction, especially schizophrenia. Therefore the present compounds can be used for the treatment of central nervous system diseases, especially schizophrenia. ED50 is lower and effect is stronger in two animal models i.e. high activity induced by MK-801 and clambering symptom induced by Apomorphine, while ED50 is higher and therapeutic index is greater in animal models of catalepsy.

Abstract: The present invention relates to the field of pharmaceutical chemistry, and in particular, to a benzopyrone derivative and a use thereof. The benzopyrone derivative is compound having a structure of formula (I) or a pharmaceutically acceptable salt thereof. It has been found by experiments that, this type of compounds is useful in prevention or treatment of neuropsychical diseases.

Abstract: The present invention belongs to the medicinal chemistry field, and specifically discloses a [1,3,4]oxadiazole derivative with the structure of general formula (I) and pharmaceutically acceptable salt thereof. The compound can be used to prepare a medicine for preventing or treating a disease of the central nervous system.